Novo Nordisk A/S (NYSE:NVO) Downgraded by Kepler Capital Markets to “Hold”

Novo Nordisk A/S (NYSE:NVO) was downgraded by Kepler Capital Markets from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

NVO has been the subject of several other research reports. HSBC restated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday. Morgan Stanley restated an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. CICC Research began coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Stock Down 16.3%

NVO stock opened at $39.68 on Tuesday. The firm’s 50-day moving average is $53.56 and its two-hundred day moving average is $53.23. The company has a market capitalization of $177.16 billion, a price-to-earnings ratio of 11.43 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $39.34 and a 52 week high of $93.80. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. raised its position in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors grew its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Boston Partners acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $310,199,000. Price T Rowe Associates Inc. MD lifted its position in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early-stage pipeline win — a China Phase 2 trial of the triple‑agonist UBT251 (GLP‑1/GIP/glucagon), developed with United Biotechnology, showed up to 19.7% mean weight loss at 24 weeks and a tolerability profile consistent with incretin therapies, which could expand Novo’s future product set beyond current semaglutide franchises. Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
• Neutral Sentiment: Wegovy/Ozempic revenue momentum remains a structural positive for the company even as sentiment sours on the pipeline; some analysts still point to strong product sales and long‑term growth from existing GLP‑1 offerings. Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
• Negative Sentiment: Major clinical setback — CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide (Zepbound/Mounjaro) in the pivotal REDEFINE‑4 head‑to‑head trial, showing weaker weight‑loss results over the trial period; this directly threatens Novo’s ability to defend/expand market share in the most valuable obesity segment. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Negative Sentiment: Quantified underperformance and market impact — reported REDEFINE‑4 numbers (e.g., ~20.2% weight loss for CagriSema vs ~23.6% for tirzepatide over 84 weeks) and the head‑to‑head loss triggered heavy selling, wiping out recent Wegovy‑era gains and pushing the stock to multi‑year lows. Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal
• Negative Sentiment: Analyst and rating pressure — at least one sell‑side analyst publicly said he’s “thrown in the towel” and firms including Deutsche Bank moved to downgrade NVO, increasing near‑term sell pressure and reducing conviction among institutional holders. Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
• Negative Sentiment: Legal/investor actions — multiple law firms and investor‑representation announcements and fraud‑investigation notices have appeared, which can prolong uncertainty and pressure sentiment even if no formal enforcement action is taken. NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.